Vitamin D3 for Life

Live Enlightened

Physiology

Bone Mineralisation, Turnover and Fractures Measure Different Outcomes

Previous related pageVitamin D, Calcium, Phosphate and Skeletal Demands in Pregnancy: Full Evidence ReviewNext related pageHow to Read Vitamin D Studies During Pregnancy
At a glance

What is the difference between bone mineralisation, turnover and fractures?

Mineralisation adds mineral to bone tissue. Turnover is the continuing removal and replacement of bone. A fracture is a break. A change in one measure does not establish a change in the others.

Did the large vitamin D trial discussed here prevent fractures?

The large fracture study did not demonstrate fewer fractures with the tested supplement regimen. Its participants were not selected for vitamin D deficiency or osteoporosis, a condition that makes bones fragile. The finding does not settle treatment in those groups.

Why can a bone mechanism be real without a supplement trial showing benefit?

The experiments may use different vitamin D forms, genetic changes, ages and outcomes. A change in bone cells or a blood marker cannot substitute for measuring fractures in people.

Read the full article below ↓

Bone mineralisation, turnover markers and fractures describe different outcomes. Vitamin D research can produce a clear result for one without establishing the others. Keeping these measurements separate helps explain how strong mechanistic findings can coexist with a null clinical fracture trial.

Mineralisation concerns the matrix receiving mineral

Lieben’s intestinal-VDR model showed accumulation of unmineralised osteoid and impaired cortical mineralisation despite maintained serum calcium. This concerns incorporation of mineral into tissue, not simply the amount of calcium circulating in blood.

The distinction between Vitamin D and Calcium and Vitamin D and Calcium Physiology is useful here. A regulated circulating concentration and accumulated skeletal mineral balance answer different questions. The study’s tissue-specific genetic intervention and mineral-rich dietary rescue do not translate directly into a human dosing rule.

Mature osteoblast/osteocyte VDR deletion was largely normal at baseline but changed the response to high calcitriol. That conditional result also shows why a receptor’s role cannot be described without the cell stage and exposure context.

Turnover markers do not identify every local cell response

CTX reflects a resorption-related process, while osteoclast counts and surfaces describe cells in particular locations. In Lieben’s work, increased serum CTX did not mean that every supplementary osteoclast measurement increased.

Mori’s toxic active-calcitriol experiment used anti-RANKL treatment and osteoblast-lineage VDR deletion to separate signalling from osteoclast output. Anti-RANKL treatment blocked osteoclast formation and CTX responses but did not eliminate every calcium or FGF23 effect. The experiment identifies a specific mechanism, not a direct human fracture estimate.

The distinction between active calcitriol and oral vitamin D3, introduced in Vitamin D Activation, is essential. A short toxic active-hormone exposure cannot be treated as an ordinary supplement trial.

Developmental recruitment is another separate outcome

Masuyama’s juvenile cartilage-VDR model altered vascular and osteoclast recruitment and osteoblast-associated FGF23. Several differences normalised by eight weeks. The study therefore concerns developmental timing as well as cell communication.

It does not identify the unknown cartilage-derived signal, prove a persistent adult phenotype or show that adult mouse growth plates fuse. The associated phosphate changes relate to Vitamin D and Phosphate Regulation, but they do not supply a measured long-term fracture outcome.

Fractures require a clinical or structural endpoint

LeBoff’s VITAL analysis directly assessed incident fractures in 25,871 adults receiving 2,000 IU vitamin D3 daily or placebo. The total-fracture hazard ratio was 0.98, with a 95% confidence interval of 0.89 to 1.08. No significant reduction was established over a median 5.3 years.

The participants were not selected for deficiency or osteoporosis, and severe deficiency was uncommon. The finding does not settle treatment of osteomalacia or every high-risk population. Conversely, mechanistic plausibility cannot replace this randomised comparison for the population studied.

The reported PTH decrease in a subset is a biochemical response, not proof of a fracture benefit or a mediating mechanism. This explanation uses the main-text fracture estimates; unavailable graphics and supplements are not used for subgroup claims.

Conclusion

The relevant question is not whether every bone-related measurement moves in the same direction, but what each experiment actually demonstrates. Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study develops the full comparison. Mineralisation, cellular remodelling and fractures each add evidence, but none should be silently substituted for another.

Primary source and publication details

Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.

Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.

Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.

LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.

Related reading

Original sources

Source

Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization

Published in The Journal of clinical investigation (2012).

Publication details

Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.

Read more →
Source

The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo

Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.

Publication details

Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.

Read more →
Source

Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts

Published in The Journal of clinical investigation (2006).

Publication details

Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.

Read more →
Source

Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults

Published in The New England journal of medicine (2022).

Publication details

LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.

Read more →